Irish researchers have made a breakthrough in treating cystic fibrosis in babies as young as one month old with a drug called Ivacaftor. This drug targets the underlying cause of the condition and has been shown to be safe and effective in newborns. The earlier the treatment is started, the better chance there is of slowing or halting the progression of cystic fibrosis. This discovery is seen as a significant moment in the treatment of cystic fibrosis, offering hope to families affected by the disease. The study has been published in the Journal of Cystic Fibrosis and further research is being conducted to extend the use of Ivacaftor to even younger infants.
Source link
CF drug may be effective in halting progression in month-old babies, Irish research shows
